Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Friedreich's Ataxia
Biotech
Lexeo acquires Mantle for $8M, adding Friedreich ataxia assets
Lexeo has agreed to acquire Mantle Therapeutics via an upfront payment of $8.3 million while locking in three strategic collaborations.
Will Maddox
Sep 22, 2026 9:58am
FDA snubs PTC's Friedreich's ataxia hopeful with CRL
Aug 19, 2025 10:55am
Lexeo locks in pivotal trial plan as gene therapy data accrue
Apr 7, 2025 9:37am
PTC bounces back with positive data on FA prospect vatiquinone
Oct 8, 2024 9:34am
Lexeo links gene therapy to improvements in rare heart disease
Jul 15, 2024 9:46am
FDA picks Denali, Neurogene and more for rare disease program
Jun 4, 2024 2:51pm
